This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Core Viewpoint - The article highlights the offerings of the Biotech Analysis Central service, which provides in-depth analysis of pharmaceutical companies and investment opportunities in the biotech sector [1][2]. Group 1: Service Offerings - Biotech Analysis Central provides a library of over 600 biotech investing articles, a model portfolio of more than 10 small and mid-cap stocks, and live chat features for investors [2]. - The service is available for $49 per month, with a discounted annual plan at $399, representing a 33.50% savings for subscribers [1]. Group 2: Analyst Background - The author, Terry Chrisomalis, is a private investor with a background in Applied Science, focusing on generating long-term value in the healthcare sector [2]. - The service aims to assist healthcare investors in making informed decisions through comprehensive analysis and news reports [2].

Core Viewpoint - The article highlights the offerings of the Biotech Analysis Central service, which provides in-depth analysis of pharmaceutical companies and investment opportunities in the biotech sector [1][2]. Group 1: Service Offerings - Biotech Analysis Central provides a library of over 600 biotech investing articles, a model portfolio of more than 10 small and mid-cap stocks, and live chat features for investors [2]. - The service is available for $49 per month, with a discounted annual plan at $399, representing a 33.50% savings for subscribers [1]. Group 2: Analyst Background - The author, Terry Chrisomalis, is a private investor with a background in Applied Science, focusing on generating long-term value in the healthcare sector [2]. - The analysis provided aims to assist healthcare investors in making informed decisions based on comprehensive research and insights [2].

14 out of the 17 largest pharmaceutical companies have now agreed to drastically lower drug prices for their American patients for the American people and patients at heavily discounted most favored nations prices. In other words, whatever the drug sells for in the world, whatever the lowest number is, if it's Germany, if it's in UK, anywhere, we will match that price. Right now, sometimes it's 10 times higher and every single American will benefit.This will have a tremendous impact on health care itself. S ...

Core Viewpoint - Viewbix Inc. is set to acquire Quantum X Labs, which has developed a groundbreaking quantum computing technology that enhances clinical trial methodologies, potentially transforming the pharmaceutical and drug discovery markets [4][5]. Group 1: Acquisition Details - Viewbix has signed a definitive agreement to acquire up to 100% (and not less than 85%) of Quantum X Labs, which includes its expanding patent portfolio [5]. - The acquisition is expected to close within 90 days from December 15, 2025, pending due diligence and regulatory approvals [5]. Group 2: Technological Advancements - Quantum X Labs has filed a provisional patent for a technology that improves Markov Chain Monte Carlo methods using quantum computing, allowing for more efficient sampling from complex probability distributions [2]. - The new methodology aims to reveal hidden biological structures and dependencies in clinical data, enabling better identification of patient clusters and treatment responses with potentially fewer samples than traditional methods [3]. Group 3: Market Implications - The advancements from Quantum X Labs could convert underpowered clinical trial datasets into robust mechanistic evidence, enhancing the success rates of personalized medicine [4]. - As quantum computing technology matures, it positions Viewbix to capture significant value in the pharmaceutical sector by reducing trial costs and timelines [4].

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

The White House is set to announce drug pricing deals with pharmaceutical heavyweights Novartis and Roche, further easing trade tensions with Switzerland after a standoff over tariffs https://t.co/0EuK0iOqUM ...

1. MSOX – AdvisorShares MSOS Daily Leveraged ETF MSOX, which seeks to achieve 2x the total daily return of the AdvisorShares Pure US Cannabis ETF (MSOS) through swap agreements, topped the list with a ~94% weekly return. The cannabis industry gained last week on the anticipation of a major policy change. President Trump's potential executive order to reclassify marijuana as a less dangerous substance sent cannabis shares soaring last week. The order is reportedly expected this week. 5. NUGT – Direxion Daily ...

The major U.S. index futures are currently pointing to a roughly flat open on Tuesday, with stocks likely to show a lack of direction after ending yesterday's choppy session modestly lower.Traders may be reluctant to make significant moves as they attempt to discern the impact of the release of mixed U.S. jobs data.While the Labor Department released a report this morning showing stronger than expected job growth in the month of November, the increase followed a notable loss of jobs in October.The report s ...

Stocks moved to the upside at the start of trading on Monday but quickly gave back ground early in the session. The major averages pulled back well off their early highs and spent much of the rest of the day lingering near the unchanged line.The major averages eventually ended the day modestly lower. While the tech-heavy Nasdaq slid 137.76 points or 0.6 percent to 23,057.41, the S&P 500 dipped 10.90 points or 0.2 percent to 6,816.51 and the Dow edged down 41.49 points or 0.1 percent at 48,416.56.The initia ...